U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, ...

They even generated clinical results that suggested it might have promise as a weight-loss drug as well — only to have Pfizer, which had agreed to fund the research, withdraw its support ...

Pfizer ’s executive team was using Mar-a-Lago for a planning meeting over several days, the people said. While there was no scheduled meeting between Bourla and Trump, the pair were likely to interact ...

The health-care sector has been rebounding recently following a sharp selloff in recent weeks amid hopes that controversy would die down. The health-care industry group was among the leading S&P 500 ...

Pfizer's stock has plummeted due to declining ... or with the discontinuation of its weight loss pill. Finally, some political pressure on the vaccine segment added recently.

San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin ...

We recently compiled a list of the 10 Best January Dividend Stocks To Buy. In this article, we are going to take a look at ...